33708346|t|Prior transfusion of umbilical cord mesenchymal stem cells can effectively alleviate symptoms of motion sickness in mice through interleukin 10 secretion.
33708346|a|BACKGROUND: Motion sickness (MS) is a disease that occurs during unbalanced movement, characterized by gastrointestinal symptoms and autonomic nervous system activation. Current clinical treatments for MS are limited. Recent evidence indicates that the levels of pro-inflammatory cytokines increase during MS and are associated with an inner ear immune imbalance. In the present study, mesenchymal stem cells (MSCs) have been shown to exert strong immuno-suppressive effects. AIM: To explore whether umbilical cord-derived mesenchymal stem cells (UC-MSCs) can prevent the occurrence of MS, and the underlying mechanism regulated by MSCs in a mouse model of MS. METHODS: A total of 144 (equal numbers of males and females) 5wkold BALB/c mice were randomly divided into five groups: Normal group (n = 16), MS group (n = 32), MSCs group (n = 32), MS + MSCs group (n = 32), and MS + AS101/MSCs group (n = 32). The MSCs group (n = 32), MS + MSCs group (n = 32), and MS + AS101/MSCs group (n = 32) were preventively transplanted with UC-MSCs or AS101-treated UC-MSCs (1 x 106 cells/mouse). Mice in the MS (n = 32), MS + MSCs, and MS + AS101/MSCs groups were subjected to rotation on a centrifuge for 10 min at 8 x g/min for MS model establishment on days 3, 5, 8, and 10 after UC-MSCs injection. The Morris water maze (MWM) test was used to observe the symptom of dizziness. Enzyme-linked immunosorbent assay (ELISA) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were used to detect the levels of inflammatory cytokines in mice peripheral blood and the petrous part of the temporal bone samples. Western blot analysis was performed to analyze the JAK2/STAT3 signaling pathway in the cochlear tissues. Histological examination was performed by hematoxylin and eosin (HE) staining for conventional morphological evaluation in the petrous part of temporal bone samples. RESULTS: The MWM test demonstrated that UC-MSCs improved the symptoms of MS. The MS + MSCs group was faster than the MS group on days 3 and 5 (P = 0.036 and P = 0.002, respectively). ELISA and RT-qPCR showed that the serum and mRNA levels of interleukin-10 (IL-10) in the cochlear tissues were increased after transplantation with UC-MSCs (MS + MSCs group vs MS group at 3 and 5 d, P = 0.002 and c P < 0.001, respectively). RT-qPCR results confirmed a significant increase in IL-10 levels at four time points (MS + MSCs group vs MS group, P = 0.009, P = 0.009, P = 0.048, and P = 0.049, respectively). This suggested that UC-MSCs reduced the sensitivity of the vestibular microenvironment by secreting IL-10. Moreover, Western blot analysis showed that the MSCs activated the JAK2/STAT3 signaling pathway in the cochlear tissues. The levels of IL-10, IL-10RA, JAK2, STAT3, and phosphorylated JAK2 and STAT3 in the MS + MSCs group were increased compared to those of the MS group (P < 0.05). The morphological changes in the four groups showed no significant differences. The role of IL-10 secretion on the ability of UC-MSCs to successfully improve the symptoms of MS was confirmed by the diminished therapeutic effects associated with treatment with the IL-10 inhibitor ammonium trichloro (dioxoethylene-o,o') tellurate (AS101). CONCLUSION: Prophylactic transplantation of UC-MSCs can alleviate the clinical symptoms of MS in mice, particularly at 3-5 d after preventive transplantation. The mechanism for UC-MSCs to reduce the sensitivity of vestibular cortex imbalance may be the secretion of IL-10. The next step is to demonstrate the possibility of curing MS in the vestibular environment by intermittent transplantation of MSCs. Above all, MSCs are expected to become a new method for the clinical prevention and treatment of MS.
33708346	97	112	motion sickness	Disease	MESH:D009041
33708346	116	120	mice	Species	10090
33708346	129	143	interleukin 10	Gene	16153
33708346	167	182	Motion sickness	Disease	MESH:D009041
33708346	184	186	MS	Disease	MESH:D009041
33708346	258	283	gastrointestinal symptoms	Disease	MESH:D012817
33708346	357	359	MS	Disease	MESH:D009041
33708346	422	444	inflammatory cytokines	Disease	MESH:D000080424
33708346	461	463	MS	Disease	MESH:D009041
33708346	565	569	MSCs	CellLine	CVCL:WG60
33708346	702	709	UC-MSCs	CellLine	CVCL:B5ZH
33708346	741	743	MS	Disease	MESH:D009041
33708346	787	791	MSCs	CellLine	CVCL:WG60
33708346	797	802	mouse	Species	10090
33708346	812	814	MS	Disease	MESH:D009041
33708346	891	895	mice	Species	10090
33708346	959	961	MS	Disease	MESH:D009041
33708346	978	982	MSCs	CellLine	CVCL:WG60
33708346	999	1001	MS	Disease	MESH:D009041
33708346	1004	1008	MSCs	CellLine	CVCL:WG60
33708346	1029	1031	MS	Disease	MESH:D009041
33708346	1034	1039	AS101	Chemical	MESH:C054105
33708346	1040	1044	MSCs	CellLine	CVCL:WG60
33708346	1065	1069	MSCs	CellLine	CVCL:WG60
33708346	1086	1088	MS	Disease	MESH:D009041
33708346	1091	1095	MSCs	CellLine	CVCL:WG60
33708346	1116	1118	MS	Disease	MESH:D009041
33708346	1127	1131	MSCs	CellLine	CVCL:WG60
33708346	1183	1190	UC-MSCs	CellLine	CVCL:B5ZH
33708346	1208	1215	UC-MSCs	CellLine	CVCL:B5ZH
33708346	1231	1236	mouse	Species	10090
33708346	1239	1243	Mice	Species	10090
33708346	1251	1253	MS	Disease	MESH:D009041
33708346	1264	1266	MS	Disease	MESH:D009041
33708346	1269	1273	MSCs	CellLine	CVCL:WG60
33708346	1279	1281	MS	Disease	MESH:D009041
33708346	1284	1289	AS101	Chemical	MESH:C054105
33708346	1290	1294	MSCs	CellLine	CVCL:WG60
33708346	1373	1375	MS	Disease	MESH:D009041
33708346	1426	1433	UC-MSCs	CellLine	CVCL:B5ZH
33708346	1513	1522	dizziness	Disease	MESH:D004244
33708346	1675	1697	inflammatory cytokines	Disease	MESH:D000080424
33708346	1701	1705	mice	Species	10090
33708346	1825	1829	JAK2	Gene	16452
33708346	1830	1835	STAT3	Gene	20848
33708346	2085	2092	UC-MSCs	CellLine	CVCL:B5ZH
33708346	2118	2120	MS	Disease	MESH:D009041
33708346	2126	2128	MS	Disease	MESH:D009041
33708346	2131	2135	MSCs	CellLine	CVCL:WG60
33708346	2162	2164	MS	Disease	MESH:D009041
33708346	2287	2301	interleukin-10	Gene	16153
33708346	2303	2308	IL-10	Gene	16153
33708346	2376	2383	UC-MSCs	CellLine	CVCL:B5ZH
33708346	2385	2387	MS	Disease	MESH:D009041
33708346	2390	2394	MSCs	CellLine	CVCL:WG60
33708346	2404	2406	MS	Disease	MESH:D009041
33708346	2521	2526	IL-10	Gene	16153
33708346	2555	2557	MS	Disease	MESH:D009041
33708346	2560	2564	MSCs	CellLine	CVCL:WG60
33708346	2574	2576	MS	Disease	MESH:D009041
33708346	2667	2674	UC-MSCs	CellLine	CVCL:B5ZH
33708346	2747	2752	IL-10	Gene	16153
33708346	2802	2806	MSCs	CellLine	CVCL:WG60
33708346	2821	2825	JAK2	Gene	16452
33708346	2826	2831	STAT3	Gene	20848
33708346	2889	2894	IL-10	Gene	16153
33708346	2896	2903	IL-10RA	Gene	16154
33708346	2905	2909	JAK2	Gene	16452
33708346	2911	2916	STAT3	Gene	20848
33708346	2937	2941	JAK2	Gene	16452
33708346	2946	2951	STAT3	Gene	20848
33708346	2959	2961	MS	Disease	MESH:D009041
33708346	2964	2968	MSCs	CellLine	CVCL:WG60
33708346	3015	3017	MS	Disease	MESH:D009041
33708346	3128	3133	IL-10	Gene	16153
33708346	3162	3169	UC-MSCs	CellLine	CVCL:B5ZH
33708346	3210	3212	MS	Disease	MESH:D009041
33708346	3300	3305	IL-10	Gene	16153
33708346	3316	3365	ammonium trichloro (dioxoethylene-o,o') tellurate	Chemical	MESH:C054105
33708346	3367	3372	AS101	Chemical	MESH:C054105
33708346	3419	3426	UC-MSCs	CellLine	CVCL:B5ZH
33708346	3466	3468	MS	Disease	MESH:D009041
33708346	3472	3476	mice	Species	10090
33708346	3552	3559	UC-MSCs	CellLine	CVCL:B5ZH
33708346	3589	3616	vestibular cortex imbalance	Disease	MESH:D015837
33708346	3641	3646	IL-10	Gene	16153
33708346	3706	3708	MS	Disease	MESH:D009041
33708346	3774	3778	MSCs	CellLine	CVCL:WG60
33708346	3791	3795	MSCs	CellLine	CVCL:WG60
33708346	3877	3879	MS	Disease	MESH:D009041
33708346	Negative_Correlation	MESH:C054105	MESH:D009041
33708346	Association	MESH:D015837	16154
33708346	Association	MESH:D009041	16153
33708346	Association	MESH:D009041	16154

